Horizon Therapeutics

Janssen Bows Out as Contender for Horizon Therapeutics Buyout
BioSpace
Mon, 12/5/22 - 10:59 am
Horizon Therapeutics
M&A
Agmen
Sanofi
Janssen
JNJ
With buyout on Horizon, Amgen and Sanofi eye cash plays for rare disease drug maker
Fierce Pharma
Fri, 12/2/22 - 11:13 am
Horizon Therapeutics
Sanofi
Amgen
M&A
Horizon still has a mountain to climb
EP Vantage
Tue, 09/13/22 - 10:39 am
Horizon Therapeutics
dazodalibep
Viela Bio
Sjögren’s syndrome
Viridian takes on Horizon
EP Vantage
Tue, 08/16/22 - 10:49 am
Horizon Therapeutics
Virdian
thyroid eye disease
VRDN-001
Tepezza
Krystexxa Chronic Gout Medication Gets Expanded FDA Approval
Xtalks
Thu, 07/14/22 - 07:53 pm
Horizon Therapeutics
Krystexxa
gout
FDA
The top 10 biopharma M&A deals in 2021
Fierce Pharma
Tue, 01/18/22 - 10:53 am
M&A
CSL
Vifor
Jazz Pharmaeuticals
GW Pharma
Novo Nordisk
Dicerna
Horizon Therapeutics
Viela Bio
Perrigo
HRA Pharma
Sanofi
Kadmon
Merck
Acceleron
Pfizer
Arena Pharmaceuticals
Translate Bio
Trillium Therapeutics
Amgen
Five Prime Therapeutics
Which drug maker spent the most on lobbying this summer? The answer will surprise you
Stat
Tue, 10/26/21 - 11:49 pm
lobbying
Horizon Therapeutics
Horizon Therapeutics Touts Five New Development Programs on R&D Day
BioSpace
Wed, 09/29/21 - 11:52 pm
Horizon Therapeutics
R&D
Horizon teams up with Olympic champion to raise awareness around Graves' disease and thyroid eye disease
Fierce Pharma
Mon, 07/12/21 - 10:36 am
Horizon Therapeutics
Graves' disease
thyroid eye disease
Horizon takes the leap into manufacturing, buying out an Irish plant with around 40 employees in tow
Endpoints
Thu, 07/1/21 - 10:48 am
Horizon Therapeutics
drug manufacturing
Ireland
Horizon lays out $65M for in-house manufacturing plant as eye med Tepezza resets course to blockbusterland
Fierce Pharma
Wed, 06/23/21 - 11:01 am
Horizon Therapeutics
drug manufactruing
Tepezza
thyroid eye disease
Orphan drug specialist Horizon looks to double down on its gout expertise with acquired rights to Arrowhead's RNAi med
Endpoints
Mon, 06/21/21 - 11:02 am
Horizon Therapeutics
gout
Krystexxa
Arrowhead Pharmaceuticals
ARO-XDH
Fortunes diverge for solo drug launchers
EP Vantage
Tue, 05/11/21 - 11:01 am
drug launches
Intra-Cellular Therapies
Biocryst
Horizon Therapeutics
Karyopharm Therapeutics
Blueprint Medicines
Zogenix
Esperion
Epizyme
Aurinia Pharmaceuticals
Global Blood Therapeutics
Quiet times return for biopharma takeouts
EP Vantage
Wed, 04/14/21 - 09:26 am
M&A
Alexion
Amgen
AstraZeneca
Biogen
Five Prime Therapeutics
Gilead Sciences
GW Pharma
Horizon Therapeutics
Immunomedics
Jazz Pharmaceutical
Kymab
Merck
Pandion
Sanofi
Viela Bio
Horizon, Roche's Genentech, AbbVie and Neurocrine rank as top pharma places to work in annual poll
Fierce Pharma
Thu, 03/18/21 - 11:01 am
Horizon Therapeutics
Roche
Genentech
AbbVie
Neurocrine
employee satisfaction
Horizon inks $3B deal to buy AstraZeneca spinout Viela for autoimmune drugs
Fierce Biotech
Mon, 02/1/21 - 10:33 am
Horizon Therapeutics
AstraZeneca
Viela Bio
autoimmune disease
R&D
M&A
Horizon Therapeutics Reports Q4 Results, Beats Revenue Target
Motley Fool
Wed, 02/26/20 - 11:21 pm
Horizon Therapeutics
earnings
FDA Approves First-Ever Treatment for Thyroid Eye Disease
Motley Fool
Tue, 01/21/20 - 11:50 pm
Horizon Therapeutics
Tepezza
thyroid eye disease
FDA
Migraine, cholesterol upstarts top the list of FDA decisions to watch this quarter
Fierce Pharma
Fri, 01/3/20 - 11:03 pm
FDA
migraines
cholesterol
Epizyme
tazemetostat
Esperion
bempedoic acid
teprotumumab
Horizon Therapeutics
Biohaven
rimegepant
FDA expert panel unanimously recommends approval for Horizon Therapeutics eye drug
Endpoints
Fri, 12/13/19 - 09:32 pm
FDA
advisory panels
Horizon Therapeutics
thyroid eye disease
teprotumumab

Pages